Cyteir Therapeutics Inc
NASDAQ:CYT
Cyteir Therapeutics Inc
Income from Continuing Operations
Cyteir Therapeutics Inc
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
C
|
Cyteir Therapeutics Inc
NASDAQ:CYT
|
Income from Continuing Operations
-$46.1m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$456m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Cyteir Therapeutics Inc's Income from Continuing Operations?
Income from Continuing Operations
-46.1m
USD
Based on the financial report for Dec 31, 2022, Cyteir Therapeutics Inc's Income from Continuing Operations amounts to -46.1m USD.
What is Cyteir Therapeutics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-45%
Over the last year, the Income from Continuing Operations growth was -9%. The average annual Income from Continuing Operations growth rates for Cyteir Therapeutics Inc have been -45% over the past three years .